Rights Issue 2022
SynAct resolves on a fully guaranteed rights issue of approximately SEK 150 million
Aktiedagen Stockholm – May 2, 2022
Sedermeradagen – April 25, 2022
AP1189
A Novel and First-in-Class Agent to Target the Melanocortin System
Our lead drug candidate AP1189, a once-daily oral selective melanocortin agonist, specifically stimulates melanocortin receptors – a distinct mode of action compared to approved anti-inflammatory drugs which can be immunosuppressive. SynAct is currently evaluating AP1189 in rheumatoid arthritis (RA), in idiopathic membranous nephropathy (iMN, an autoimmune disease associated with the development of nephrotic syndrome) and in the treatment of respiratory insufficiency caused by COVID-19 infection.
-
May 20, 2022 RegulatoryBulletin from the annual general meeting in SynAct Pharma AB on May 20, 2022
-
May 18, 2022 Non RegulatorySynact Pharma to present at the ABGSC Life Science Summit
-
April 29, 2022 RegulatorySynAct Pharma AB publishes Annual Report 2021
-
February 11, 2022 RegulatoryAnnual Results 2021
